NovaBay Pharmaceuticals, Inc. (NBY)
$0.6805
Rating:
Recommendation:
Buy
| Symbol | NBY |
|---|---|
| Price | $0.6805 |
| Beta | 2.728 |
| Volume Avg. | 0.47M |
| Market Cap | 2.865M |
| Shares () | - |
| 52 Week Range | 0.48-12.6 |
| 1y Target Est | - |
| DCF Unlevered | NBY DCF -> | |
|---|---|---|
| DCF Levered | NBY LDCF -> | |
| ROE | -89.05% | Strong Sell |
| ROA | -78.50% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 55.38% | Buy |
| P/E | -0.06 | Neutral |
| P/B | 0.04 | Neutral |
Latest NBY news
About
Download (Excel)NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.